Obesity among outpatients with major depressive disorder

George I. Papakostas, Timothy Petersen, Dan V. Iosifescu, Alana M. Burns, Andrew A. Nierenberg, Jonathan E. Alpert, Jerrold F. Rosenbaum, Maurizio Fava

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Studies focusing on the prevalence of obesity in major depressive disorder (MDD), or the impact of excess body fat on the treatment of MDD are lacking. The aim of the present work is to systematically study obesity in MDD outpatients. A total of 369 MDD outpatients enrolled in an 8-wk trial of 20 mg fluoxetine had height and weight measured at baseline. We then examined: (1) the prevalence of being overweight or obese, (2) the relationship between obesity and a number of demographic and clinical variables, and, (3) the relationship between relative body weight and obesity with clinical response. We found that more than 50% of patients were overweight [body mass index (BMI) ≥ 25 kg/m2], while 20% were obese (BMI ≥ 30 kg/m2). Obese patients presented with worse somatic well-being scores than non-obese MDD patients, but they did not differ with respect to depression severity, anxiety, somatic complaints, hopelessness or hostility. Greater relative body weight, but not obesity, predicted non-response. In conclusion, greater relative body weight was found to place MDD outpatients at risk for fluoxetine resistance.

Original languageEnglish (US)
Pages (from-to)59-63
Number of pages5
JournalInternational Journal of Neuropsychopharmacology
Volume8
Issue number1
DOIs
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

Major Depressive Disorder
Outpatients
Obesity
Fluoxetine
Body Weight
Body Mass Index
Hostility
Adipose Tissue
Anxiety
Demography
Depression
Weights and Measures

Keywords

  • Fluoxetine treatment
  • Major depressive disorder
  • Obesity

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Papakostas, G. I., Petersen, T., Iosifescu, D. V., Burns, A. M., Nierenberg, A. A., Alpert, J. E., ... Fava, M. (2005). Obesity among outpatients with major depressive disorder. International Journal of Neuropsychopharmacology, 8(1), 59-63. https://doi.org/10.1017/S1461145704004602

Obesity among outpatients with major depressive disorder. / Papakostas, George I.; Petersen, Timothy; Iosifescu, Dan V.; Burns, Alana M.; Nierenberg, Andrew A.; Alpert, Jonathan E.; Rosenbaum, Jerrold F.; Fava, Maurizio.

In: International Journal of Neuropsychopharmacology, Vol. 8, No. 1, 03.2005, p. 59-63.

Research output: Contribution to journalArticle

Papakostas, GI, Petersen, T, Iosifescu, DV, Burns, AM, Nierenberg, AA, Alpert, JE, Rosenbaum, JF & Fava, M 2005, 'Obesity among outpatients with major depressive disorder', International Journal of Neuropsychopharmacology, vol. 8, no. 1, pp. 59-63. https://doi.org/10.1017/S1461145704004602
Papakostas, George I. ; Petersen, Timothy ; Iosifescu, Dan V. ; Burns, Alana M. ; Nierenberg, Andrew A. ; Alpert, Jonathan E. ; Rosenbaum, Jerrold F. ; Fava, Maurizio. / Obesity among outpatients with major depressive disorder. In: International Journal of Neuropsychopharmacology. 2005 ; Vol. 8, No. 1. pp. 59-63.
@article{81f9cdaaf800448380bda7ccc39b0cc6,
title = "Obesity among outpatients with major depressive disorder",
abstract = "Studies focusing on the prevalence of obesity in major depressive disorder (MDD), or the impact of excess body fat on the treatment of MDD are lacking. The aim of the present work is to systematically study obesity in MDD outpatients. A total of 369 MDD outpatients enrolled in an 8-wk trial of 20 mg fluoxetine had height and weight measured at baseline. We then examined: (1) the prevalence of being overweight or obese, (2) the relationship between obesity and a number of demographic and clinical variables, and, (3) the relationship between relative body weight and obesity with clinical response. We found that more than 50{\%} of patients were overweight [body mass index (BMI) ≥ 25 kg/m2], while 20{\%} were obese (BMI ≥ 30 kg/m2). Obese patients presented with worse somatic well-being scores than non-obese MDD patients, but they did not differ with respect to depression severity, anxiety, somatic complaints, hopelessness or hostility. Greater relative body weight, but not obesity, predicted non-response. In conclusion, greater relative body weight was found to place MDD outpatients at risk for fluoxetine resistance.",
keywords = "Fluoxetine treatment, Major depressive disorder, Obesity",
author = "Papakostas, {George I.} and Timothy Petersen and Iosifescu, {Dan V.} and Burns, {Alana M.} and Nierenberg, {Andrew A.} and Alpert, {Jonathan E.} and Rosenbaum, {Jerrold F.} and Maurizio Fava",
year = "2005",
month = "3",
doi = "10.1017/S1461145704004602",
language = "English (US)",
volume = "8",
pages = "59--63",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "1",

}

TY - JOUR

T1 - Obesity among outpatients with major depressive disorder

AU - Papakostas, George I.

AU - Petersen, Timothy

AU - Iosifescu, Dan V.

AU - Burns, Alana M.

AU - Nierenberg, Andrew A.

AU - Alpert, Jonathan E.

AU - Rosenbaum, Jerrold F.

AU - Fava, Maurizio

PY - 2005/3

Y1 - 2005/3

N2 - Studies focusing on the prevalence of obesity in major depressive disorder (MDD), or the impact of excess body fat on the treatment of MDD are lacking. The aim of the present work is to systematically study obesity in MDD outpatients. A total of 369 MDD outpatients enrolled in an 8-wk trial of 20 mg fluoxetine had height and weight measured at baseline. We then examined: (1) the prevalence of being overweight or obese, (2) the relationship between obesity and a number of demographic and clinical variables, and, (3) the relationship between relative body weight and obesity with clinical response. We found that more than 50% of patients were overweight [body mass index (BMI) ≥ 25 kg/m2], while 20% were obese (BMI ≥ 30 kg/m2). Obese patients presented with worse somatic well-being scores than non-obese MDD patients, but they did not differ with respect to depression severity, anxiety, somatic complaints, hopelessness or hostility. Greater relative body weight, but not obesity, predicted non-response. In conclusion, greater relative body weight was found to place MDD outpatients at risk for fluoxetine resistance.

AB - Studies focusing on the prevalence of obesity in major depressive disorder (MDD), or the impact of excess body fat on the treatment of MDD are lacking. The aim of the present work is to systematically study obesity in MDD outpatients. A total of 369 MDD outpatients enrolled in an 8-wk trial of 20 mg fluoxetine had height and weight measured at baseline. We then examined: (1) the prevalence of being overweight or obese, (2) the relationship between obesity and a number of demographic and clinical variables, and, (3) the relationship between relative body weight and obesity with clinical response. We found that more than 50% of patients were overweight [body mass index (BMI) ≥ 25 kg/m2], while 20% were obese (BMI ≥ 30 kg/m2). Obese patients presented with worse somatic well-being scores than non-obese MDD patients, but they did not differ with respect to depression severity, anxiety, somatic complaints, hopelessness or hostility. Greater relative body weight, but not obesity, predicted non-response. In conclusion, greater relative body weight was found to place MDD outpatients at risk for fluoxetine resistance.

KW - Fluoxetine treatment

KW - Major depressive disorder

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=15244361696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15244361696&partnerID=8YFLogxK

U2 - 10.1017/S1461145704004602

DO - 10.1017/S1461145704004602

M3 - Article

VL - 8

SP - 59

EP - 63

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 1

ER -